For Medicaid, the top 10 list includes several psychotherapeutic medications, reflecting the important role that Medicaid plays in meeting the needs of people with mental illness.

In particular, for Medicare Part D, the top 10 list includes treatments for cancer, chronic obstructive pulmonary disease, and high cholesterol which are more commonly used by older adults. Despite the overlap, the ranking of these drug products generally differs across payers, and there is also variation in which products have the largest total spending for each payer, which reflects the different types of populations covered. There is additional overlap in the top 10 lists for large employer plans and Medicaid, including treatments for attention-deficit/hyperactivity disorder (ADHD) and HIV. Antidiabetic agents, antivirals and psychotherapeutics are among the top therapeutic classes by total spending in large employer plans, Medicare Part D, and Medicaid.ДЄmong the top 10 drug products with the highest total spending in large employer plans, Medicare Part D, and Medicaid, there are two products in common: Harvoni, a treatment for hepatitis C, and Lantus Solostar, an insulin therapy for diabetes.Out-of-pocket drug spending per user among people in large employer plans and Medicare Part D is highest for drugs to treat cancer, multiple sclerosis and rheumatoid arthritis.While some of the same drug products appear among the top 10 drug products with the highest total spending in large employer plans, Medicare Part D, and Medicaid, there is also variation that reflects differing covered populations.For spending on specific drug products, the top five drug products with the highest total spending alone account for at least 10% of total prescription drug spending in large employer plans, Medicare Part D, and Medicaid.in 2017, while patients paid 14% of the total as out-of-pocket payments. Private health insurance, Medicare, and Medicaid accounted for 82% of total retail prescription drug spending in the U.S.This variation in the types of individuals covered by each payer is reflected in some of the patterns of prescription drug spending and use presented below. Employers cover a population that is healthier than either Medicare or Medicaid, and almost all covered workers have coverage for prescription drugs.People 65 and older and those with disabilities who also have Medicare coverage receive coverage of retail prescription drugs through Medicare Part D. Medicaid is the nationвЂ™s health insurance program for people with low income and provides a wide array of medical and long-term care benefits to a diverse population of low-income children and adults, individuals with disabilities, and people ages 65 and older.MedicareвЂ™s prescription drug benefit is provided through the Part D program to Medicare beneficiaries who enroll in private stand-alone drug plans or Medicare Advantage drug plans.

Medicare covers adults ages 65 and older and younger people with long-term disabilities.

Spending by private health insurers, Medicare, and Medicaid accounts for a majority of prescription drug spending in the U.S., but the types of individuals who receive prescription drug coverage from these three payers varies: Rebates differ by payer, and are estimated to be larger for Medicaid than Medicare Part D or private employers. This analysis compares prescription drug spending and use in large private employer plans, Medicare Part D, and Medicaid, based primarily on claims data by payer, which does not account for rebates. Rising drug prices affect patientsвЂ™ out-of-pocket costs as well as the budgets of private and public payers, though the challenges vary by payer. Prescription drug costs are a pressing concern for both consumers and policymakers.

Red book drugs price list